Connect your AI

Ultragenyx Pharmaceutical RARE Debt-to-assets

Debt-to-assets at other companies

Eli LillyLLY

0.4×-0.1×

AmgenAMGN

0.6×0.0×

Ionis PharmaceuticalsIONS

0.2×+0.1×

Arrowhead ResearchARWR

0×0.0×

CRISPR TherapeuticsCRSP

0.3×+0.2×

ModernaMRNA

0.1×+0.1×

Other financials

Income statement

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

total debt/total assets=0×

Based on the most recent quarter.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ultragenyx Pharmaceutical's debt-to-assets?: Ultragenyx Pharmaceutical (RARE) reported debt-to-assets of 0× in Q4 2025.
How has Ultragenyx Pharmaceutical's debt-to-assets changed year-over-year?: Ultragenyx Pharmaceutical's debt-to-assets decreased by 12.3% year-over-year, from 0× to 0×.
What is the long-term trend for Ultragenyx Pharmaceutical's debt-to-assets?: Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's debt-to-assets has grown at a -3.0% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?: Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.